PRESEPSIN VERSUS OTHER INFLAMMATORY MARKERS FOR THE DIAGNOSIS OF ACUTE BACTERIAL INFECTIONS IN CHRONIC HEMODIALYSIS PATIENTS

2020 ◽  
Vol 0 (0) ◽  
pp. 0-0
Author(s):  
Manal Negm ◽  
Muhammad Abdel Ghafar ◽  
Reham Elkhouly
2004 ◽  
Vol 27 (10) ◽  
pp. 835-841 ◽  
Author(s):  
C-T. Lee ◽  
C-H. Lee ◽  
Y. Su ◽  
Y-C. Chuang ◽  
T-L. Tsai ◽  
...  

2012 ◽  
Vol 3 (4) ◽  
pp. 151-154
Author(s):  
Dr. Jaya S Dr. Jaya S ◽  
◽  
Dr. Mariraj J Dr. Mariraj J ◽  
Dr. Krishna. S Dr. Krishna. S

2020 ◽  
Vol 21 (10) ◽  
pp. 1011-1026
Author(s):  
Bruna O. Costa ◽  
Marlon H. Cardoso ◽  
Octávio L. Franco

: Aminoglycosides and β-lactams are the most commonly used antimicrobial agents in clinical practice. This occurs because they are capable of acting in the treatment of acute bacterial infections. However, the effectiveness of antibiotics has been constantly threatened due to bacterial pathogens producing resistance enzymes. Among them, the aminoglycoside-modifying enzymes (AMEs) and β-lactamase enzymes are the most frequently reported resistance mechanisms. AMEs can inactivate aminoglycosides by adding specific chemical molecules in the compound, whereas β-lactamases hydrolyze the β-lactams ring, preventing drug-target interaction. Thus, these enzymes provide a scenario of multidrug-resistance and a significant threat to public health at a global level. In response to this challenge, in recent decades, several studies have focused on the development of inhibitors that can restore aminoglycosides and β-lactams activity. In this context, peptides appear as a promising approach in the field of inhibitors for future antibacterial therapies, as multiresistant bacteria may be susceptible to these molecules. Therefore, this review focused on the most recent findings related to peptide-based inhibitors that act on AMEs and β-lactamases, and how these molecules could be used for future treatment strategies.


2015 ◽  
Vol 30 (suppl_3) ◽  
pp. iii619-iii620
Author(s):  
Ruta Vaiciuniene ◽  
Irmante Stramaityte ◽  
Edita Ziginskiene ◽  
Vytautas Kuzminskis ◽  
Inga Arune Bumblyte

2005 ◽  
Vol 15 (2) ◽  
pp. 217-224 ◽  
Author(s):  
Karen M. Majchrzak ◽  
Lara B. Pupim ◽  
Kong Chen ◽  
Cathi J. Martin ◽  
Sheila Gaffney ◽  
...  

2020 ◽  
Vol 10 (1) ◽  
pp. 4
Author(s):  
Romain Vial ◽  
Marion Gully ◽  
Mickael Bobot ◽  
Violaine Scarfoglière ◽  
Philippe Brunet ◽  
...  

Background: Daily management to shield chronic dialysis patients from SARS-CoV-2 contamination makes patient care cumbersome. There are no screening methods to date and a molecular biology platform is essential to perform RT-PCR for SARS-CoV-2; however, accessibility remains poor. Our goal was to assess whether the tools routinely used to monitor our hemodialysis patients could represent reliable and quickly accessible diagnostic indicators to improve the management of our hemodialysis patients in this pandemic environment. Methods: In this prospective observational diagnostic study, we recruited patients from La Conception hospital. Patients were eligible for inclusion if suspected of SARS-CoV-2 infection when arriving at our center for a dialysis session between March 12th and April 24th 2020. They were included if both RT-PCR result for SARS-CoV-2 and cell blood count on the day that infection was suspected were available. We calculated the area under the curve (AUC) of the receiver operating characteristic curve. Results: 37 patients were included in the final analysis, of which 16 (43.2%) were COVID-19 positive. For the day of suspected COVID-19, total leukocytes were significantly lower in the COVID-19 positive group (4.1 vs. 7.4 G/L, p = 0.0072) and were characterized by lower neutrophils (2.7 vs. 5.1 G/L, p = 0.021) and eosinophils (0.01 vs. 0.15 G/L, p = 0.0003). Eosinophil count below 0.045 G/L identified SARS-CoV-2 infection with AUC of 0.9 [95% CI 0.81—1] (p < 0.0001), sensitivity of 82%, specificity of 86%, a positive predictive value of 82%, a negative predictive value of 86% and a likelihood ratio of 6.04. Conclusions: Eosinophil count enables rapid routine screening of symptomatic chronic hemodialysis patients suspected of being COVID-19 within a range of low or high probability.


Sign in / Sign up

Export Citation Format

Share Document